Newron Pharmaceuticals reports that recent research in the journal “Neuropsychopharmacology” underline the potential of Evenamide in the treatment of schizophrenia. This preclinical study conducted at the University of Pittsburgh demonstrates the effectiveness of Evenamide to target the main pathology of schizophrenia, hippocampus. The drug relieves positive, negative and cognitive symptoms in a model of schizophrenia.
Sannume, a first-class glutamate modulator, has prolonged effects beyond the elimination of the drug, indicating potential impact on neuronal plasticity. It offers an innovative approach by targeting hippocampal hyperexcitability, absent from current treatments, thus offering hope to patients with resistant schizophrenia.
This research corroborates the results of the previous phase II and III tests, suggesting the effectiveness of Evenamide in the significant improvement in symptoms. Thanks to its favorable security profiles compared to existing antipsychotics, Evenamide could revolutionize the processing strategies of schizophrenia.
R. H.
